Background

The Global Burden of Disease study estimated that in 2016 there were 5.5 million deaths and 116.4 million disability-adjusted life years (DALYs) lost due to stroke, making it the second most common cause of death worldwide. Due to the significant burden stroke has been designated as one of the priorities by the World Health Organization. 87% of DALYs lost due to stroke and 86% of stroke-related mortality occurs in LMICs. A recent survey of 17 African countries demonstrated that there were only 5 stroke units and 2 designated stroke centers.  
 

MT stands as a revolutionary breakthrough in the field of neurosurgery and interventional neurology, redefining the treatment landscape for patients suffering acute ischemic stroke caused by large vessel occlusion. Several randomized controlled trials (RCTs) have demonstrated that compared to standard medical management, endovascular intervention with mechanical thrombectomy is associated with significantly improved outcomes. The procedure's remarkable efficacy has led to its rapid adoption as the standard of care in many well-resourced healthcare settings. However, the challenge remains in extending this treatment modality to regions with limited medical infrastructure. The Mechanical Thrombectomy Global Access For Stroke (MT-GLASS) study, demonstrated that global access to mechanical thrombectomy is <3% of the demand, and <1% in most LMICs. 

 

We need your consent to load the translations

We use a third-party service to translate the website content that may collect data about your activity. Please review the details and accept the service to view the translations.